Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perifosine in Metastatic or Recurrent Malignant Melanoma
NCT00053781Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jun 2003
- Primary completion
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of perifosine in Malignant Melanoma (MM), sponsored by Canadian Cancer Trials Group. Primary endpoints: Response Rate and Toxicity Assessment. Started Jun 2003; status: completed.
02
Drugs
perifosine
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00053781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053781.